Prostate Cancer - Results from #60

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. October 25, 2024

Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy. October 25, 2024

The use of focal therapy for the treatment of prostate cancer in Canada: Where are we, how did we get here, and where are we going? October 25, 2024

The homeodomain regulates stable DNA binding of prostate cancer target ONECUT2. October 24, 2024

Clinical Factors Associated with Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA <0.5 ng/mL. October 24, 2024

Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards. October 24, 2024

Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis. October 24, 2024

Optimizing prostate cancer detection in transition zone: an analysis of apparent diffusion coefficient values in prostate magnetic resonance imaging evaluation with Prostate Imaging Reporting and Data System (PI-RADS) assessment. October 24, 2024

Acute pancreatitis and biliary obstruction from metastatic lymph node compression during [177Lu] Lu-PSMA-617 therapy: a case report. October 23, 2024

Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α-Catenin. October 23, 2024

Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey. October 23, 2024

Effect of Prednisone Dosing on Mineralocorticoid-Related Side Effects With Abiraterone in Prostate Cancer. October 23, 2024

Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer. October 23, 2024

Castration Levels of Testosterone Results in Atrophy of Androgen-Sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism. October 22, 2024

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer. October 22, 2024

Comparison of Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) and Prostate Imaging after Focal Ablation (PI-FAB) for Detecting Recurrent Prostate Cancer at Prostate MRI. October 22, 2024

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. October 22, 2024

Optimizing risk stratification for intermediate-risk prostate cancer - the prognostic value of baseline health-related quality of life. October 22, 2024

Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer. October 22, 2024

Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers October 21, 2024

Page 4 of 1436